296 related articles for article (PubMed ID: 30858122)
1. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways.
Essam RM; Ahmed LA; Abdelsalam RM; El-Khatib AS
Life Sci; 2019 Apr; 222():245-254. PubMed ID: 30858122
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system.
Jabaris SS; Sumathy H; Girish R; Narayanan S; Sugumar M; Saravana Babu C; Thanikachalam S; Thanikachalam M
Brain Res; 2015 Oct; 1622():279-91. PubMed ID: 26168894
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice.
Wang B; Zhu X; Yu S; Xue H; Deng L; Zhang Y; Zhang Y; Liu Y
Biochem Biophys Res Commun; 2024 Aug; 722():150170. PubMed ID: 38797152
[TBL] [Abstract][Full Text] [Related]
4. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
Izikki M; Raffestin B; Klar J; Hatzelmann A; Marx D; Tenor H; Zadigue P; Adnot S; Eddahibi S
J Pharmacol Exp Ther; 2009 Jul; 330(1):54-62. PubMed ID: 19386793
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.
Saroj P; Bansal Y; Singh R; Akhtar A; Sodhi RK; Bishnoi M; Sah SP; Kuhad A
Inflammopharmacology; 2021 Apr; 29(2):499-511. PubMed ID: 33517508
[TBL] [Abstract][Full Text] [Related]
6. Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats.
Jabaris SG; Sumathy H; Kumar RS; Narayanan S; Thanikachalam S; Babu CS
Eur J Pharmacol; 2015 Jan; 746():138-47. PubMed ID: 25446433
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
[TBL] [Abstract][Full Text] [Related]
8. In Silico, Ex Vivo and In Vivo Studies of Roflumilast as a Potential Antidiarrheal and Antispasmodic agent: Inhibition of the PDE-4 Enzyme and Voltage-gated Ca++ ion Channels.
Rehman NU; Ansari MN; Samad A
Molecules; 2020 Feb; 25(4):. PubMed ID: 32102361
[TBL] [Abstract][Full Text] [Related]
9. A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling.
Wójcik-Pszczoła K; Chłoń-Rzepa G; Jankowska A; Ślusarczyk M; Ferdek PE; Kusiak AA; Świerczek A; Pociecha K; Koczurkiewicz-Adamczyk P; Wyska E; Pękala E; Gosens R
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32503342
[TBL] [Abstract][Full Text] [Related]
10. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.
Ding H; Li N; He X; Liu B; Dong L; Liu Y
Int Urol Nephrol; 2017 Oct; 49(10):1723-1730. PubMed ID: 28756610
[TBL] [Abstract][Full Text] [Related]
11. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.
Kwak HJ; Park KM; Choi HE; Chung KS; Lim HJ; Park HY
Cell Signal; 2008 May; 20(5):803-14. PubMed ID: 18276108
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
Tao X; He H; Peng J; Xu R; Fu J; Hu Y; Li L; Yang X; Feng X; Zhang C; Zhang L; Yu X; Shen A; Huang K; Fu Q
Pharmacol Res; 2022 Jan; 175():106004. PubMed ID: 34826603
[TBL] [Abstract][Full Text] [Related]
13. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
Togo S; Liu X; Wang X; Sugiura H; Kamio K; Kawasaki S; Kobayashi T; Ertl RF; Ahn Y; Holz O; Magnussen H; Fredriksson K; Skold CM; Rennard SI
Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L959-69. PubMed ID: 19304913
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of phosphodiesterase IV enzyme improves locomotor and sensory complications of spinal cord injury via altering microglial activity: Introduction of Roflumilast as an alternative therapy.
Moradi K; Golbakhsh M; Haghighi F; Afshari K; Nikbakhsh R; Khavandi MM; Faghani S; Badripour A; Etemadi A; Ashraf-Ganjouei A; Bagheri S; Dehpour AR
Int Immunopharmacol; 2020 Sep; 86():106743. PubMed ID: 32619958
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
Cortijo J; Iranzo A; Milara X; Mata M; Cerdá-Nicolás M; Ruiz-Saurí A; Tenor H; Hatzelmann A; Morcillo EJ
Br J Pharmacol; 2009 Feb; 156(3):534-44. PubMed ID: 19154443
[TBL] [Abstract][Full Text] [Related]
16. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
[TBL] [Abstract][Full Text] [Related]
17. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis‑induced Acute Kidney Injury.
Xu X; Liao L; Hu B; Jiang H; Tan M
Med Sci Monit; 2020 May; 26():e921319. PubMed ID: 32449901
[TBL] [Abstract][Full Text] [Related]
19. Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP.
El-Ashmawy NE; Khedr NF; El-Bahrawy HA; El-Adawy SA
Int Immunopharmacol; 2018 Mar; 56():36-42. PubMed ID: 29331766
[TBL] [Abstract][Full Text] [Related]
20. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Mokry J; Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D
J Physiol Pharmacol; 2017 Oct; 68(5):721-730. PubMed ID: 29375047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
